Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ramsey Baghdadi
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.
Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.
Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.
The rebate rule is dead, but we should pay tribute to the failed endeavor.
Price justification legislation is advancing in both chambers of Congress. But CBO scores them as no savings.
Broad bipartisan support and billions in projected savings mean that bill may finally pass. But whether it will work as intended to improve generic access to market remains as questionable as ever.